MX356486B - Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa. - Google Patents

Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa.

Info

Publication number
MX356486B
MX356486B MX2014001842A MX2014001842A MX356486B MX 356486 B MX356486 B MX 356486B MX 2014001842 A MX2014001842 A MX 2014001842A MX 2014001842 A MX2014001842 A MX 2014001842A MX 356486 B MX356486 B MX 356486B
Authority
MX
Mexico
Prior art keywords
phenylethylidene
substituted
compounds
histone demethylase
inhiitors
Prior art date
Application number
MX2014001842A
Other languages
English (en)
Other versions
MX2014001842A (es
Inventor
David J Bearss
Hariprasad Vankayalapati
Venkataswamy Sorna
Steve L Warner
Sunil Sharma
Bret Stephens
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of MX2014001842A publication Critical patent/MX2014001842A/es
Publication of MX356486B publication Critical patent/MX356486B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

En un aspecto, la invención se relaciona con análogos de (E)-N'-(1 -feniletiliden)benzohidrazida sustituidos, derivados de los mismos, y compuestos relacionados, que son útiles como inhibidores de la histona desmetilasa específica de la lisina, incluyendo LSD1; métodos sintéticos para hacer los compuestos; composiciones farmacéuticas que comprenden los compuestos; y métodos para utilizar los compuestos y composiciones para tratar trastornos asociados con la disfunción de la LSD1; este resumen se pretende como una herramienta de exploración para los propósitos de investigación en la técnica particular, y no pretende ser limitante de la presente invención.
MX2014001842A 2011-08-15 2012-08-15 Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa. MX356486B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161523801P 2011-08-15 2011-08-15
PCT/US2012/050948 WO2013025805A1 (en) 2011-08-15 2012-08-15 Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors

Publications (2)

Publication Number Publication Date
MX2014001842A MX2014001842A (es) 2014-07-24
MX356486B true MX356486B (es) 2018-05-30

Family

ID=47715455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001842A MX356486B (es) 2011-08-15 2012-08-15 Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa.

Country Status (26)

Country Link
US (2) US8987335B2 (es)
EP (1) EP2744330B1 (es)
JP (1) JP6122006B2 (es)
KR (1) KR101983537B1 (es)
CN (1) CN103929960B (es)
AU (1) AU2012296639B2 (es)
BR (1) BR112014003382B1 (es)
CA (1) CA2843609C (es)
CY (1) CY1123345T1 (es)
DK (1) DK2744330T3 (es)
EA (1) EA026389B1 (es)
ES (1) ES2821548T3 (es)
HK (1) HK1200052A1 (es)
HR (1) HRP20201433T1 (es)
HU (1) HUE050962T2 (es)
IL (1) IL230728A (es)
IN (1) IN2014CN00961A (es)
LT (1) LT2744330T (es)
MX (1) MX356486B (es)
PL (1) PL2744330T3 (es)
PT (1) PT2744330T (es)
SG (1) SG2014009609A (es)
SI (1) SI2744330T1 (es)
SM (1) SMT202000551T1 (es)
WO (1) WO2013025805A1 (es)
ZA (1) ZA201400881B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
CN104981458B (zh) 2012-10-02 2017-07-21 吉利德科学公司 组蛋白去甲基化酶抑制剂
SG10201707027SA (en) * 2013-02-27 2017-09-28 Epitherapeutics Aps Inhibitors of histone demethylases
EP2968282B1 (en) * 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
CA2915817C (en) * 2013-06-19 2022-12-13 University Of Utah Research Foundation Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015153516A1 (en) 2014-04-04 2015-10-08 University Of Florida Research Foundation Hdac inhibitor compounds and methods of treatment
EP3151821A4 (en) * 2014-06-05 2017-12-13 The University of Kansas Marmelin analogs and methods of use in cancer treatment
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
KR20170040805A (ko) 2014-08-27 2017-04-13 길리애드 사이언시즈, 인코포레이티드 히스톤 데메틸라제를 억제하기 위한 화합물 및 방법
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
CN106146361A (zh) * 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
US11427543B2 (en) 2016-07-19 2022-08-30 The General Hospital Corporation Compounds for targeting cancer stem cells
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
US20190256929A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US20200069677A1 (en) 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
CN106831489B (zh) * 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
CA3071804A1 (en) 2017-08-03 2019-02-07 Oryzon Genomics, S.A. Use of a kdm1a inhibitor in the treatment of behavior alterations
AU2018316542B2 (en) 2017-08-18 2023-02-16 Istituto Europeo Di Oncologia (Ieo) S.R.L. Indole derivatives as histone demethylase inhibitors
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109793742A (zh) * 2019-03-04 2019-05-24 四川大学华西医院 一种药物化合物应用
CN109758442B (zh) * 2019-03-20 2021-08-17 武汉大学 二芳基酰肼类化合物在制备抗流感病毒药物中的应用
HRP20260110T1 (hr) 2019-03-20 2026-03-13 Oryzon Genomics, S.A. Vafidemstat za liječenje neagresivnih simptoma graničnog poremećaja osobnosti
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
WO2022020804A1 (en) * 2020-07-24 2022-01-27 Salarius Pharmaceuticals Llc Methods of inhibiting lysine-specific demethylase 1 (lsd-1)
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
MX2023011779A (es) 2021-04-08 2023-11-22 Oryzon Genomics Sa Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides.
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN116077661B (zh) * 2022-08-22 2024-09-27 沈阳药科大学 Kdm1a抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525118A (ja) * 2001-01-22 2004-08-19 アルパイダ　アーゲー 新規ヒドラゾン類
JP2002302472A (ja) * 2001-01-31 2002-10-18 Meiji Seika Kaisha Ltd メイラード反応阻害剤
KR20060054308A (ko) 2003-07-16 2006-05-22 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 피부 색소침착의 치료제
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
TW200800145A (en) 2005-08-26 2008-01-01 Dekk Tec Inc Hydrazone agents to treat cutaneous lesions
CA2626846A1 (en) 2005-11-03 2007-05-18 Redpoint Bio Corporation Hydrazone derivatives and uses thereof
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
JP2010518008A (ja) 2007-02-02 2010-05-27 レッドポイント バイオ コーポレイション インスリンおよびｇｌｐ−１の放出を調節するｔｒｐｍ５阻害物質
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
EP2195029A2 (en) * 2007-08-24 2010-06-16 Oryzon Genomics SA Treatment and prevention of neurodegenerative diseases
AR070898A1 (es) * 2008-03-18 2010-05-12 Solvay Pharm Bv Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
EP2307440A4 (en) 2008-07-01 2012-12-19 Zacharon Pharmaceuticals Inc HEPARAN SULFATE INHIBITORS
BRPI1006840A2 (pt) * 2009-01-14 2019-09-24 Dow Agrosciences Llc composições fungicidas que incluem derivados de hidrazona e cobre
US20110189306A1 (en) * 2010-01-13 2011-08-04 Norbert Kartner COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES

Also Published As

Publication number Publication date
SI2744330T1 (sl) 2020-11-30
IL230728A0 (en) 2014-03-31
BR112014003382A2 (pt) 2017-11-21
IN2014CN00961A (es) 2015-04-10
WO2013025805A1 (en) 2013-02-21
DK2744330T3 (da) 2020-09-07
EP2744330B1 (en) 2020-07-15
US20140094445A1 (en) 2014-04-03
CY1123345T1 (el) 2022-03-24
EA201490453A1 (ru) 2014-09-30
CA2843609A1 (en) 2013-02-21
CN103929960A (zh) 2014-07-16
AU2012296639B2 (en) 2016-06-09
KR101983537B1 (ko) 2019-05-29
EP2744330A1 (en) 2014-06-25
EA026389B1 (ru) 2017-04-28
JP2014527531A (ja) 2014-10-16
US20150150864A1 (en) 2015-06-04
MX2014001842A (es) 2014-07-24
NZ621078A (en) 2015-10-30
SG2014009609A (en) 2014-05-29
US9555024B2 (en) 2017-01-31
ZA201400881B (en) 2015-07-29
JP6122006B2 (ja) 2017-04-26
HK1200052A1 (en) 2015-07-31
HUE050962T2 (hu) 2021-01-28
BR112014003382B1 (pt) 2022-03-15
ES2821548T3 (es) 2021-04-26
CN103929960B (zh) 2016-08-17
LT2744330T (lt) 2020-10-26
EP2744330A4 (en) 2015-03-25
CA2843609C (en) 2020-12-08
SMT202000551T1 (it) 2020-11-10
PL2744330T3 (pl) 2020-12-14
US8987335B2 (en) 2015-03-24
HRP20201433T1 (hr) 2020-12-11
KR20140077887A (ko) 2014-06-24
IL230728A (en) 2017-05-29
AU2012296639A1 (en) 2014-03-06
PT2744330T (pt) 2020-10-01

Similar Documents

Publication Publication Date Title
MX356486B (es) Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa.
WO2014194280A3 (en) Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
MX2015018032A (es) Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MX382569B (es) Compuesto de carboxamida, sulfonamida y amina para trastornos metabolicos.
EA201490357A1 (ru) Индазолы
BR112013025387A2 (pt) análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
WO2014055934A3 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
WO2014055928A3 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
GEP201706735B (en) Kinase inhibitors
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
MX363019B (es) Composicion saborizante que comprende mentol y mentano-carboxamidas.
ECSP14030538A (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
PE20150224A1 (es) Inhibidores del nampt
MX350862B (es) Acidos de piperidinil naftilacetico.
WO2013006734A8 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
PH12015500795B1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
CL2012002541A1 (es) Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros.
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ

Legal Events

Date Code Title Description
FG Grant or registration